Zai Lab is part of a local innovative pharmaceutical company in China
.
After eight years of development, Zai Lab has established 28 differentiated and innovative product pipelines
, driven by internal R&D and strategic cooperation.
Zai Lab currently has four products commercialized
in Greater China.
Among them, benefiting from the rapid increase of ovarian cancer first-line indications after being included in medical insurance, Zeile achieved revenue of US$34.
1 million in the second quarter of 2022, a year-on-year increase of 46%, and as of the first half of 2022, Zele had nearly 1,700 hospital admissions
.
At the end of June 2022, EpShield has been included in 50 Huimin insurance, most of which can achieve sickness reimbursement
.
A commercial product in the field of gastrointestinal oncology, Qingle, has been included in 73 Huimin Insurance
in the first half of 2022.
In the past 2022, Zai Lab has also made many important progress
.
For example, the company has announced positive data from pivotal/Phase 3 clinical trials for several products, including: TTFields, a Phase 3 study of non-small cell lung cancer (NSCLC); Data from a phase 3 study of the drug KarXT for the treatment of schizophrenia in adults, etc
.
Zai Lab and Novocure also recently announced that the pivotal LUNAR study for non-small cell lung cancer met its primary endpoint, demonstrating statistically significant and clinically significant improvements
in overall survival compared to standard therapy alone.
And this news also made Zai Lab's stock price rise
sharply within a period of time.
Zai Lab has set itself a goal of having at least 15 marketed products that can cover more than 30 indications
by 2025.
According to relevant reports, Zai Lab will have a number of expected milestones in the next 2023
.
For example, efgartigimod injection α(efgartigimod) is expected to be approved
in 2023.
It is reported that this is an FcRn antagonist, which has been declared for marketing in China in 2022 for the treatment of generalized myasthenia gravis (gMG); The Company may release data from a Phase 3 clinical trial for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in the second quarter of 2023; Data from the Phase 3 trial for patients with polycythemia vera (PV) and immune thrombocytopenia (ITP) will be published in the second half of 2023
.
In 2023, Zai Lab may announce Phase 3 clinical data on TTFields in ovarian cancer; In mid-2023, an FGFR2b monoclonal antibody bemarituzumab is expected to join the global phase 3 clinical trial FORTITUDE-101, which is targeted for the first-line treatment
of gastric cancer with FGFR2b overexpression.
In addition, the report shows that KarXT: an innovative drug combining the novel muscarinic agonist Sinomerin with the approved muscarinic antagonist trosparonium chloride, is expected to initiate bridging studies in China in the second quarter of 2023 for patients with schizophrenia;
Sulbactam-durlobactam: A combination of β-lactam/β-lactamase inhibitor with unique antibacterial activity against Acinetobacter baumannii, including carbapenem-resistant strains, it has been declared for marketing in China in 2022 and is expected to be approved in the first half of 2023 for infections
caused by carbapene-resistant strains (CRAB).
Zai Lab said that with the development of China's aging and the needs of the people to upgrade their pharmaceutical consumption, including disease spectrum and market demand are constantly changing, there are still a large number of unmet medical needs
in the fields of oncology, autoimmunity, and central nervous system.
How to develop innovative products to quickly meet these unmet medical needs and provide patients with best-in-class or first-of-its-kind innovative therapies will be the company's biggest test
in this industry.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];